Erythropoietin Safety and Efficacy in AIDS-Related Anemia
Epoetin alfa
Blood-Borne Infections+17
+ Urogenital Diseases
+ Genital Diseases
Treatment Study
Summary
This study focuses on AIDS patients who experience anemia, a condition where the body lacks enough healthy red blood cells. This anemia can be caused by the disease itself or by a medication used to treat AIDS, called zidovudine (AZT). The goal of the study is to understand the safety and effectiveness of a drug called erythropoietin, or r-HuEPO, in managing this anemia. The potential outcomes of this study could provide a new treatment option for AIDS patients suffering from anemia, improving their quality of life. During the study, participants receive either r-HuEPO or a placebo, a substance that has no therapeutic effect. Neither the participants nor the researchers know who receives which, ensuring the results are unbiased. The study measures the safety and effectiveness of r-HuEPO by evaluating changes in the participants' red blood cell count and any side effects that may occur. The results of this study could help determine if r-HuEPO is a safe and effective treatment for anemia in AIDS patients.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 75 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location